232 related articles for article (PubMed ID: 31183877)
1. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
[TBL] [Abstract][Full Text] [Related]
2. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
3. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal anti-CD47 interference in red cell and platelet testing.
Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
[TBL] [Abstract][Full Text] [Related]
5. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
Kim TY; Yoon MS; Hustinx H; Sim J; Wan HI; Kim H
Transfusion; 2020 Oct; 60(10):2399-2407. PubMed ID: 32820530
[TBL] [Abstract][Full Text] [Related]
6. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
[No Abstract] [Full Text] [Related]
7. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
[TBL] [Abstract][Full Text] [Related]
8. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
[TBL] [Abstract][Full Text] [Related]
10. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
Mei Z; Wool GD
Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI; Lakhani N; Patnaik A; Shah SA; Chandana SR; Rasco D; Colevas AD; O'Rourke T; Narayanan S; Papadopoulos K; Fisher GA; Villalobos V; Prohaska SS; Howard M; Beeram M; Chao MP; Agoram B; Chen JY; Huang J; Axt M; Liu J; Volkmer JP; Majeti R; Weissman IL; Takimoto CH; Supan D; Wakelee HA; Aoki R; Pegram MD; Padda SK
J Clin Oncol; 2019 Apr; 37(12):946-953. PubMed ID: 30811285
[TBL] [Abstract][Full Text] [Related]
12. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
Transfusion; 2024 May; ():. PubMed ID: 38767410
[TBL] [Abstract][Full Text] [Related]
13. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
[TBL] [Abstract][Full Text] [Related]
14. A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia patients with intensive chemotherapy.
Byun JM; Park W; Shin DY; Koh Y; Kim I; Yoon SS; Park JH; Kim H; Hong J
Blood Transfus; 2023 Nov; 21(6):479-487. PubMed ID: 37235735
[TBL] [Abstract][Full Text] [Related]
15. Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion.
Reyland L; Dwight M; Bullock T; Latham T; Lord K; Wardle A; Palmer D; Eggington J; Callaghan T; Seals D; Kulkarni S
Transfus Med; 2020 Apr; 30(2):157-160. PubMed ID: 31914482
[No Abstract] [Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
Swoboda DM; Sallman DA
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
[TBL] [Abstract][Full Text] [Related]
18. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody.
Xu Z; Gao J; Yao J; Yang T; Wang D; Dai C; Ding Y
FEBS Open Bio; 2021 Mar; 11(3):813-825. PubMed ID: 33449453
[TBL] [Abstract][Full Text] [Related]
20. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
